Data Updates in GI Cancers and HCC from ESMO 2024 - Episode 1

5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC

,

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.